Clinical Trial Search

Primary: The Primary Outcome is a Composite of the Following Three Clinical Outcomes: 1) Severe PPH Defined as Blood Loss ≥1000 ml or; 2) Postpartum Laparotomy for Bleeding or…

Primary: Cause of Death — 20; 35; 56; 50 Participants

Primary: All-cause, Pregnancy-related Mortality — 41; 47; 50 Participants — p=0.05

Primary: Post-discharge Readmission or Mortality — 231; 349 Participants

Primary: Difference in Actual Blood Volume and Estimated Blood Volume in Milliliters. — -20.8; -41.7; -53.5; -96.0 milliliters — p=<0.05

Primary: PK Model Parameter Estimates — 8.85; 10.39; 9.45 L/hr

Primary: Success Rate Calculated Based on Collection of Fetal Heart Rate Data From Investigational Devices on Subjects Enrolled in Each Gestational Age Group — 85.01; 92.27…

Primary: Change From Baseline Resilience at 4 Weeks — 26.57; 28.29; 1.85 score on a scale — p=<.001

Primary: Change in Maternal Hemoglobin Level — 1.1; 2.1 g/dL

Primary: Umbilical Artery Malondialdehyde — 9.8; 10.2 umol/L

Primary: Successful Expulsion of Fetus and Placenta Within 48 Hours — 60; 47 participants — p=<0.05

Primary: Prenatal Education Knowledge Rate — 29.61; 21.64; 5.38; 13.35 questions — p=0.001

Primary: Infant Mortality Through 6 mo of Age — 764; 741 participants — p=0.36

Primary: Knowledge Pretest Score — 77.08; 80.19 score on a scale — p=0.32

Primary: Number of Participants With Excessive Bleeding as Determined by the Composite Outcome Criteria — 78; 75 Participants — p=0.5

Primary: Number of Participants With Need for Additional Uterotonics (Methylergonovine, Carboprost, Misoprostol) — 80; 80 Participants

Primary: Number of Participants With Postpartum Hemorrhage (PPH) — 409; 399; 111; 125 Participants — p=0.33

Primary: Time to Bleeding Control After AAJT-S Device Application — 2 Minutes

Primary: Rate of COVID-19 Vaccination (6 Month) — 251; 130 Participants

Primary: Clinical Estimated Blood Loss (EBL) Between Cases and Controls Using Clinical Estimate Versus Device Assessment — 800; 800 milliLiters

Primary: Proportion of Participants With Recorded Blood Pressure Values in Office — 43; 44; 49; 56 Participants

Primary: Quantitative Blood Loss — 840; 1051 milliliters — p=<0.05

Primary: Gestational Weight Gain (GWG) — 12; 10 kg — p=0.01

Primary: Neonatal Mortality Rate at 28 Days in <5th Percentile Birth Weight Infants (as a Proxy Measure for Prematurity) — 566; 524 Participants — p=0.65

Primary: Neonatal Mortality — 46; 37 Participants — p=0.314

Primary: Cervix Elasticity — 54; 19.7 kPa

Primary: Composite Perinatal Morbidity — 277; 203; 221; 45 participants

Primary: Number of Subjects Reporting Uterine Atony or Postpartum Hemorrhage Requiring Medical (Medication or Blood Transfusion), Surgical or Other Interventional Treatment — 45…

Primary: The Presence or Absence of Cell Free Fetal DNA in Maternal Blood in the Setting of a Failed Pregnancy. — 50 percentage of participants

Primary: Opioid Use Disorder (OUD) and Other Substance Use Disorder (SUD) Treatment Linkage/Retention — -1.5; -8.8 Percentage of days